Argenica Therapeutics (ASX:AGN) has announced results from a more extensive preclinical study assessing the efficacy of ARG-007 in a rat model of moderate traumatic brain injury (TBI).
The company said the results suggest ARG-007 can prevent axonal injury and neuroinflammation, which significantly contribute to the acute and chronic consequences of TBI.
This study expands on Argenica’s previously announced rat pilot study in moderate TBI3, which was undertaken again in the laboratory of Professor Lindy Fitzgerald at Curtin University and the Perron Institute for Neurological and Translational Sciences.
The study assessed the therapeutic potential of ARG-007 in reducing axonal injury and neuroinflammation following moderate TBI and resulting behavioural outcomes.
The aim was to confirm the results of the pilot study and ensure that the therapeutic effect of ARG-007 could be replicated multiple times in preclinical studies.
Managing director Dr Liz Dallimore said, “We are extremely pleased with the results from this larger preclinical study in a moderate TBI animal model. The study confirms previously generated data, indicating that ARG-007 consistently reduces axonal injury and neuroinflammation following TBI, and encouragingly to levels similar to non-injured animals. We will continue to progress further larger animal studies in TBI to ensure rigorous scientific validation of ARG-007 in TBI as a therapeutic target”.